Trial Profile
A trial to assess the value of non-invasive tools evaluating early the response to bevacizumab in non-small lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Dec 2015 New trial record